What are the current treatment guidelines for squamous cell carcinoma of the lung?

Current Treatment Guidelines for Squamous Cell Lung Cancer

For patients with advanced squamous cell lung cancer and good performance status (PS 0-1), pembrolizumab plus carboplatin and paclitaxel (or nab-paclitaxel) is the standard first-line treatment, regardless of PD-L1 expression. 1

First-Line Treatment Strategy

Performance Status 0-1 Patients

Immunotherapy-Based Combinations (Preferred)

• Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel is the standard choice for metastatic squamous NSCLC in patients with PS 0-1, provided there are no contraindications to immunotherapy 1

• Atezolizumab + carboplatin + nab-paclitaxel represents an alternative option for PS 0-1 patients with metastatic squamous NSCLC, though with slightly lower evidence strength 1

• Nivolumab + ipilimumab is a treatment option for patients with high tumor mutational burden (TMB), regardless of PD-L1 expression level 1

• Durvalumab + tremelimumab + platinum-based chemotherapy may be considered, though benefit in squamous histology appears more modest 1

Special Consideration for High PD-L1 Expression (≥50%)

• Single-agent pembrolizumab should be considered in eligible patients with PS 0-1 and PD-L1 tumor proportion score (TPS) ≥50% 1
• This represents a chemotherapy-free option with improved quality of life compared to chemotherapy 1

Chemotherapy-Only Regimens (When Immunotherapy Contraindicated)

• Platinum-based doublets with third-generation cytotoxic agents (gemcitabine, vinorelbine, taxanes) are recommended when immunotherapy is contraindicated 1

• Necitumumab + gemcitabine + cisplatin represents an option for advanced squamous cell carcinoma expressing EGFR by immunohistochemistry, though with lower evidence strength 1

• Administer 4 cycles of platinum-based doublets followed by maintenance monotherapy, or up to a maximum of 6 cycles in patients not suitable for maintenance 1

Performance Status 2 Patients

• Carboplatin-based combination therapy should be considered in eligible PS 2 patients, as chemotherapy prolongs survival and improves quality of life compared to best supportive care 1

• Single-agent chemotherapy with gemcitabine, vinorelbine, or docetaxel represents an alternative treatment option 1

Performance Status 3-4 Patients

• Best supportive care is recommended for poor PS (3-4) patients 1

Critical Exclusions for Squamous Cell Carcinoma

Pemetrexed is contraindicated in squamous cell lung cancer and should be restricted to non-squamous NSCLC in any line of treatment 1

Bevacizumab is not recommended for squamous histology due to safety concerns, particularly risk of pulmonary hemorrhage 1, 2

Maintenance Therapy

• Continuation maintenance with gemcitabine is an option in patients treated with 4 cycles of cisplatin-gemcitabine 1

• Continuation maintenance with necitumumab may be considered if used in first-line treatment 1

• Maintenance should only be offered to patients with PS 0-1 after first-line chemotherapy 1

Second-Line Treatment Following Progression

After Chemotherapy (Immunotherapy-Naive)

• Nivolumab is a preferred option (Level I, A evidence) 1

• Pembrolizumab (if PD-L1 ≥1%) is a preferred option (Level I, A evidence) 1

• Atezolizumab is a preferred option (Level I, A evidence) 1

• Docetaxel or ramucirumab + docetaxel are chemotherapy alternatives 1

After Immunotherapy

• Limited prospective data exist for this scenario 3
• Ramucirumab + docetaxel warrants consideration based on real-world data 3
• Afatinib may be an option following immunochemotherapy combinations 3
• Docetaxel, gemcitabine, or platinum-based chemotherapy may be options for select patients 3

Essential Clinical Considerations

Smoking Cessation

• Should be highly encouraged at any stage of NSCLC, as it improves outcomes 1

Molecular Testing

• Routine molecular testing is generally not performed for squamous cell carcinoma given the low prevalence of oncogenic driver mutations 4
• Consider testing in patients with light/never smoking history, adenosquamous histology, or when histological diagnosis is not definitive 4
• EGFR testing should be performed in select squamous NSCLC patients, and if positive, genotypically-driven therapy should be pursued ahead of chemotherapy or immunotherapy 1

Treatment Duration

• Chemotherapy should be initiated while the patient maintains good performance status 1
• For most patients, 4 cycles of chemotherapy are recommended, with a maximum of 6 cycles 1

Common Pitfall

The most critical error is using pemetrexed or bevacizumab in squamous cell carcinoma—these agents are either contraindicated or lack efficacy in this histology and should be strictly avoided 1, 2.